Literature DB >> 22318658

A histopathological diagnostic marker for human spinal astrocytoma: expression of glial fibrillary acidic protein-δ.

Dong Hwa Heo1, Se Hoon Kim, Kyung-Moo Yang, Yong Jun Cho, Keung Nyun Kim, Do Heum Yoon, Tae-Cheon Kang.   

Abstract

Although histopathological diagnosis of spinal cord astrocytomas is important for postoperative treatment planning and prognosis, there is a lack of reliable immunohistochemical markers. The purpose of our study was to assess the expression pattern of GFAP-δ in spinal cord astrocytomas in human patients and to evaluate the utility of GFAP-δ as an immunohistochemical diagnostic marker. A total of 22 patients with spinal cord astrocytic tumors were included in this study. Patients were classified according to the WHO designation of human astrocytic tumors; three patients had grade 1 astrocytomas, 14 had grade 2, and five had Grade 3. Normal control spinal cord tissues were obtained at autopsy from the cervical spinal cords of ten patients with no history of cervical trauma or neurological disease. We evaluated BRAF, IDH1, GFAP, and GFAP-δ immunoreactivity in control tissues and astrocytomas. In normal control tissues, GFAP immunoreactivity was detected in astrocytes whereas GFAP-δ immunoreactivity was observed in very few astrocytes adjacent to the subpial layer of the spinal cord. GFAP-δ immunoreactivity was significantly correlated with spinal cord astrocytoma grade in astrocytomas compared to that in normal control tissues. The optical density of GFAP-δ increased significantly with astrocytoma grade (correlation coefficient, R (2) = 0.680). Also, BRAF and IDH1 immunoreactivity were detected in astrocytoma. We suggest that GFAP-δ may be an additional, reliable histopathological diagnostic marker for spinal cord astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318658     DOI: 10.1007/s11060-012-0801-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

1.  A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS.

Authors:  Peng Yang; K Adam Baker; Theo Hagg
Journal:  J Comp Neurol       Date:  2005-09-19       Impact factor: 3.215

Review 2.  Prognostic factors in intramedullary astrocytomas: a literature review.

Authors:  Vladimír Benes; Pavel Barsa; Vladimír Benes; Petr Suchomel
Journal:  Eur Spine J       Date:  2009-06-28       Impact factor: 3.134

3.  Intramedullary spinal cord tumors in children under the age of 3 years.

Authors:  S Constantini; J Houten; D C Miller; D Freed; M M Ozek; L B Rorke; J C Allen; F J Epstein
Journal:  J Neurosurg       Date:  1996-12       Impact factor: 5.115

Review 4.  The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.

Authors:  Andreas von Deimling; Andrey Korshunov; Christian Hartmann
Journal:  Brain Pathol       Date:  2011-01       Impact factor: 6.508

Review 5.  Pathologic analysis of primary brain tumors.

Authors:  R D McComb; P C Burger
Journal:  Neurol Clin       Date:  1985-11       Impact factor: 3.806

6.  Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms.

Authors:  E M Hol; R F Roelofs; E Moraal; M A F Sonnemans; J A Sluijs; E A Proper; P N E de Graan; D F Fischer; F W van Leeuwen
Journal:  Mol Psychiatry       Date:  2003-09       Impact factor: 15.992

7.  Glial fibrillary acidic protein filaments can tolerate the incorporation of assembly-compromised GFAP-delta, but with consequences for filament organization and alphaB-crystallin association.

Authors:  Ming-Der Perng; Shu-Fang Wen; Terry Gibbon; Jinte Middeldorp; Jacqueline Sluijs; Elly M Hol; Roy A Quinlan
Journal:  Mol Biol Cell       Date:  2008-08-06       Impact factor: 4.138

8.  Enhanced glial fibrillary acidic protein-delta expression in human astrocytic tumor.

Authors:  Kyung-Chan Choi; Sung-Eun Kwak; Ji-Eun Kim; Seung Hun Sheen; Tae-Cheon Kang
Journal:  Neurosci Lett       Date:  2009-07-30       Impact factor: 3.046

9.  Expression patterns of glial fibrillary acidic protein (GFAP)-delta in epilepsy-associated lesional pathologies.

Authors:  L Martinian; K Boer; J Middeldorp; E M Hol; S M Sisodiya; W Squier; E Aronica; M Thom
Journal:  Neuropathol Appl Neurobiol       Date:  2009-08       Impact factor: 8.090

10.  Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Authors:  Andrey Korshunov; Jochen Meyer; David Capper; Arne Christians; Marc Remke; Hendrik Witt; Stefan Pfister; Andreas von Deimling; Christian Hartmann
Journal:  Acta Neuropathol       Date:  2009-06-19       Impact factor: 17.088

View more
  10 in total

1.  A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation.

Authors:  Seong Jun Ryu; Jong Yul Kim; Kyung Hyun Kim; Jeong Yoon Park; Sung Uk Kuh; Dong Kyu Chin; Keun Su Kim; Yong Eun Cho; Se Hoon Kim
Journal:  Eur Spine J       Date:  2016-03-16       Impact factor: 3.134

Review 2.  GFAP Alternative Splicing and the Relevance for Disease - A Focus on Diffuse Gliomas.

Authors:  Jessy V van Asperen; Pierre A J T Robe; Elly M Hol
Journal:  ASN Neuro       Date:  2022 Jan-Dec       Impact factor: 5.200

3.  Synemin: an evolving role in tumor growth and progression.

Authors:  Shailendra Kapoor
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-05-28       Impact factor: 12.910

4.  GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence.

Authors:  Rebeca Uceda-Castro; Jessy V van Asperen; Claire Vennin; Jacqueline A Sluijs; Emma J van Bodegraven; Andreia S Margarido; Pierre A J Robe; Jacco van Rheenen; Elly M Hol
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

Review 5.  GFAPδ: A Promising Biomarker and Therapeutic Target in Glioblastoma.

Authors:  Roxana Radu; George E D Petrescu; Radu M Gorgan; Felix M Brehar
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

6.  GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.

Authors:  Zihan Ran; Jingcheng Yang; Yaqing Liu; XiuWen Chen; Zijing Ma; Shaobo Wu; Yechao Huang; Yueqiang Song; Yu Gu; Shuo Zhao; Mengqi Fa; Jiangjie Lu; Qingwang Chen; Zehui Cao; Xiaofei Li; Shanyue Sun; Tao Yang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

7.  GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease.

Authors:  Willem Kamphuis; Carlyn Mamber; Martina Moeton; Lieneke Kooijman; Jacqueline A Sluijs; Anne H P Jansen; Monique Verveer; Lody R de Groot; Vanessa D Smith; Sindhoo Rangarajan; José J Rodríguez; Marie Orre; Elly M Hol
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

8.  GFAPδ/GFAPα ratio directs astrocytoma gene expression towards a more malignant profile.

Authors:  Oscar M J A Stassen; Emma J van Bodegraven; Fabrizio Giuliani; Martina Moeton; Regina Kanski; Jacqueline A Sluijs; Miriam E van Strien; Willem Kamphuis; Pierre A J Robe; Elly M Hol
Journal:  Oncotarget       Date:  2017-10-04

9.  GFAP isoforms control intermediate filament network dynamics, cell morphology, and focal adhesions.

Authors:  Martina Moeton; Oscar M J A Stassen; Jacqueline A Sluijs; Vincent W N van der Meer; Liselot J Kluivers; Hedde van Hoorn; Thomas Schmidt; Eric A J Reits; Miriam E van Strien; Elly M Hol
Journal:  Cell Mol Life Sci       Date:  2016-05-03       Impact factor: 9.261

10.  Importance of GFAP isoform-specific analyses in astrocytoma.

Authors:  Emma J van Bodegraven; Jessy V van Asperen; Pierre A J Robe; Elly M Hol
Journal:  Glia       Date:  2019-01-22       Impact factor: 7.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.